Literature DB >> 8360477

Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction.

T Yin1, T Taga, M L Tsang, K Yasukawa, T Kishimoto, Y C Yang.   

Abstract

IL-11 is a novel cytokine with a variety of biofunctions which overlap with those of IL-6. We have previously identified IL-11 specific binding protein which is distinct from that of IL-6 in a number of cell lines. The similarities in biofunctions and differences in ligand binding proteins between IL-11 and IL-6 prompted us to investigate whether IL-11 shares common signal transduction mechanisms with IL-6. We have examined early signals triggered by IL-11 or IL-6 in a multifactor-dependent human erythroleukemic cell line, TF-1. The results showed that IL-11 and IL-6 can both stimulate cell proliferation, induce similar pattern of protein tyrosine phosphorylation, and activate the same proto-oncogene (junB) expression in TF-1 cells. These findings imply that IL-11 and IL-6 share similar early signaling events with the possibility of using the same signal transducer, gp130. We next tested whether IL-11 induced signaling can be inhibited by anti-gp130 antibodies which blocked IL-6-mediated functions. It was observed that anti-gp130 antibodies abolished cell proliferation, protein tyrosine phosphorylation, and junB gene expression elicited by IL-11 or IL-6 in TF-1 cells. The same antibodies, however, had no effect on granulocyte-macrophage colony stimulating factor or erythropoietin-induced TF-1 cell proliferation. Finally, anti-IL-6R antibody inhibited the ability of IL-6, but not IL-11, to transduce early signals in TF-1 cells. These results demonstrate that IL-11 and IL-6 utilize different ligand binding proteins, but share common signal transducer, gp130, in TF-1 cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360477

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution.

Authors:  J G Zhang; C M Owczarek; L D Ward; G J Howlett; L J Fabri; B A Roberts; N A Nicola
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

2.  Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.

Authors:  Masahiko Hayashi; Mun-Chual Rho; Akiko Enomoto; Akiko Fukami; Yong-Pil Kim; Yuji Kikuchi; Toshiaki Sunazuka; Tomoyasu Hirose; Kanki Komiyama; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

3.  Effects of interleukin-11 on the expression of human bone sialoprotein gene.

Authors:  Hiroyoshi Matsumura; Yohei Nakayama; Hideki Takai; Yorimasa Ogata
Journal:  J Bone Miner Metab       Date:  2014-03-15       Impact factor: 2.626

4.  Differential inhibitory effects of indomethacin, dexamethasone, and interferon-gamma (IFN-gamma) on IL-11 production by rheumatoid synovial cells.

Authors:  H Taki; E Sugiyama; T Mino; A Kuroda; M Kobayashi
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

5.  Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions.

Authors:  H Dahmen; U Horsten; A Küster; Y Jacques; S Minvielle; I M Kerr; G Ciliberto; G Paonessa; P C Heinrich; G Müller-Newen
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  IL-11 antagonist suppresses Th17 cell-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis.

Authors:  Xin Zhang; Nazanin Kiapour; Sahil Kapoor; Joseph R Merrill; Yongjuan Xia; Woomi Ban; Stephanie M Cohen; Bentley R Midkiff; Valerie Jewells; Yen-Yu I Shih; Silva Markovic-Plese
Journal:  Clin Immunol       Date:  2018-08-24       Impact factor: 3.969

8.  Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model.

Authors:  B E Barton; J Shortall; J V Jackson
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

Review 9.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

10.  The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family.

Authors:  U M Wegenka; C Lütticken; J Buschmann; J Yuan; F Lottspeich; W Müller-Esterl; C Schindler; E Roeb; P C Heinrich; F Horn
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.